The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy

Cancers · Published 2026-07-31 · DOI 10.3390/cancers18152461

Free full text

Authors (2)

Takafumi Morisaki, Takashi Morisaki

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Morisaki, T., Morisaki, T. (2026). The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy. Cancers. https://doi.org/10.3390/cancers18152461

Related articles

• Bridging clinical gaps in personalized cancer neoantigen vaccines · Cancer Cell · 2026 · Cites or is cited by this article
• Trans-Presentation of IL-15 by IL15Rα Attenuates Tumor Immune Surveillance and Is Dispensable for IL-15-Dependent Tumor Growth Control · Cancers · 2026 · Same journal
• Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review · Cancers · 2026 · Same journal
• Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study · Cancers · 2026 · Same journal
• Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications · Cancers · 2026 · Same journal
• Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management · Cancers · 2026 · Same journal
• Ex Vivo Line-Field Confocal Optical Coherence Tomography and Ex Vivo Fusion Confocal Microscopy for Lateral-Margin Assessment of Basal Cell Carcinoma in Correlation with Histopathology: A Prospective Pilot Diagnostic-Accuracy Study · Cancers · 2026 · Same journal
• Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023 · Cancers · 2026 · Same journal
• PTEN Protein Loss in Diagnostic Prostate Biopsies Is Associated with Gleason Score Upgrading in Radical Prostatectomy · Cancers · 2026 · Same journal
• Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma · Cancers · 2026 · Same journal